Latest Conference

A concerted effort to increase flu vaccination during the COVID-19 pandemic resulted in more protection among a high-risk population, as well as educational opportunities for pharmacy students.

Rates of in-hospital mortality and days with bacteremia were similar between the two study cohorts.

Antimicrobials were commonly prescribed during the first wave of the pandemic, and clinicians were successfully guided by antimicrobial stewardship programs.

Increased facility-level vaccine coverage amongst residents and staff was associated with lower cases in the latter population.

More than half of urine cultures were found to be contaminated and 1 in 5 of the patients were prescribed an antibiotic.

Social identity plays an important role in how antimicrobial stewards see their roles and influences how they communicated with prescribers.

A comparative study of same-day and seven-day TB test results show there is little difference in HIV treatment adherence or outcomes at 48 weeks.

Phase 1/2 trial results showed the immunomodulary vaccine regimen could induce significant T-cell response in patients with HIV.

A bamlanivimab study showed a 72% reduction in the incidence of COVID-19 and an 80% reduction of progression in the virus in residents in assisted living facilities and nursing staff.

While at the earliest stages of potential development, long-acting/extended release (LA/ER) formulations for treatment and prevention of TB could be something to be studied in the future.

Index testing declined in countries including Malawi, Lesotho and Zimbabwe.

Deep learning models identified the largest differences in resting state network topology occurred.

Plasma proteome confirmed the association between cellular and humoral SARS-CoV-2 immunity.

The prognostic proteins identified can serve as the basis of future pathway and network analyses.

Dapivrine (DPV) was studied in 1-month and 3-month durations.

During the pandemic, reduced HIV testing led to concerns about getting people diagnosed and on antiretroviral therapy (ART), and achieving viral suppression (VS).

Johns Hopkins data suggest men are being hospitalized more frequently with infection, and are facing more severe outcomes.

MN titers showed a striking increase after just 1 dose in experienced subjects.

COVID-19 has further highlighted the need for innovative models that minimize face-to-face contact in HCV treatment.

ViiV Healthcare’s investigational therapy, GSK’254, demonstrated antiviral activity, safety, and tolerability in its phase 2a proof-of-concept findings.

Convalescent plasma treatment was found not to improve survival or disease course in the patient group.

Gut microbiome is known to release enzymes that degrade plasma glycans which regulate inflammation.

With the highest HIV incidence rate in this part of the country, the need to get people from diagnosis to timely antiretroviral therapy (ART) remains an urgent need.

New research from the Emerman Lab at Fred Hutchinson shows potential for advancing HIV-1 life cycle understanding.

Presented at CROI, investigators have identified sex-modified inflammatory predictors of cardiovascular and VTE risks among patients with HIV.

Merck has developed its investigational islatravir subdermal implant for prevention of HIV infection, and it is going to be studied for a long-term delivery of up to 1 year.

14 weeks of oral alendronate taken prior to ART had a sustained impact on prevention of bone loss at the hip.

Increased hospitalization risk was driven mainly by the high burden of comorbidities in both groups.